MEDICINE DETAILS
Rinvoq
Active ingredient: Upadacitinib
The EMA record identifies Rinvoq as upadacitinib prolonged-release tablets in 15 mg, 30 mg and 45 mg strengths. FDA records also include Rinvoq LQ 1 mg/mL oral solution; that U.S. presentation must not be shown as an EU tablet or pack.
NEXT STEP
Choose the strength and pack
✓ If you are unsure, choose “I do not know”.
These options are not medical advice, a dosing recommendation, stock confirmation or a sale offer.
ABOUT THIS MEDICINE
What is Rinvoq used for?
Rinvoq (upadacitinib) is a Janus kinase (JAK) inhibitor indicated for the treatment of adults with:
- Moderate to severe active rheumatoid arthritis (RA)
- Psoriatic arthritis
- Atopic dermatitis
- Ulcerative colitis
- Ankylosing spondylitis (AS)
It is used for patients with RA for whom disease-modifying anti-rheumatic medicines (DMARDs) or methotrexate did not work well enough. It can be used on its own (monotherapy) or with methotrexate.
It is available in extended-release tablet form, each containing 15 mg of upadacitinib.
This information is general and is not medical advice. Talk to your doctor or pharmacist about any treatment decision.
RECORDED PRODUCT PROFILE
Rinvoq identity, dosage form and pack information.
The details below are assembled from current catalogue records. They must still be checked against the prescription, medicine box and an official regulatory record.
OFFICIAL RECORD SUMMARY
Product details checked against regulatory sources
The EMA record identifies Rinvoq as upadacitinib prolonged-release tablets in 15 mg, 30 mg and 45 mg strengths. FDA records also include Rinvoq LQ 1 mg/mL oral solution; that U.S. presentation must not be shown as an EU tablet or pack.
- ✓EU 15 mg prolonged-release tablets — packs of 28, 30, 84, 90 or 98
- ✓EU 30 mg prolonged-release tablets — packs of 28, 30, 90 or 98
- ✓EU 45 mg prolonged-release tablets — pack of 28
- ✓U.S. record also includes Rinvoq LQ 1 mg/mL oral solution in a 180 mL bottle; this is not an EU tablet presentation
Presentations can differ by jurisdiction and authorisation. This list is not a use or dosing recommendation.
Recorded strength and pack options
Each row is shown only to help identify the product; it is not stock confirmation or a sale offer.
-
15 mg · 30 tablets Catalogue organisation: AbbVie Deutschland GmbH & Co. KG
-
15 mg · 90 tablets Catalogue organisation: AbbVie Deutschland GmbH & Co. KG
-
15 mg modified-release tablets · 98 tablets Catalogue organisation: Orifarm GmbH
-
30 mg · 30 tablets Catalogue organisation: AbbVie Deutschland GmbH & Co. KG
-
30 mg · 90 tablets Catalogue organisation: AbbVie Deutschland GmbH & Co. KG
-
45 mg modified-release tablets · 28 tablets Catalogue organisation: Abacus Medicine A/S
OFFICIAL SOURCES
Check the Rinvoq record at an official source.
Search for “Rinvoq” or “Upadacitinib”. Finding a product in one source does not by itself confirm stock, authorisation in a particular country or suitability for a patient.
OFFICIAL EXTERNAL SOURCE
European Medicines Agency (EMA)
Search medicines evaluated by EMA by brand name or active substance. EMA also links to national registers for nationally authorised products.
↗ OFFICIAL EXTERNAL SOURCE Drugs@FDASearch FDA-approved human drug records by brand name or active ingredient, including current labelling where available.
↗ PRODUCT-SPECIFIC OFFICIAL RECORD EMA — Rinvoq EPAREuropean public assessment and authorised presentation information for Rinvoq.
↗ PRODUCT-SPECIFIC OFFICIAL RECORD FDA — Rinvoq and Rinvoq LQ prescribing informationFDA-approved U.S. information distinguishing tablets from Rinvoq LQ oral solution.
↗SERVICE BOUNDARY
Information checking and independent enquiry support for Rinvoq.
OrphanDrug helps organise the product identity and recorded strength and pack details for an enquiry. It does not sell, take payment for, prescribe, import, dispense or deliver medicines.
Clinical decision: Only a qualified healthcare professional who has assessed the patient can decide whether a product, form or dose is appropriate.
CLEAR ANSWERS
Frequently asked questions about Rinvoq
01What is Rinvoq?＋
This directory record associates the brand name Rinvoq with the active ingredient Upadacitinib. The brand and ingredient are shown for product identification only, not as treatment or dosing advice.
02Which Rinvoq strengths and packs are recorded?＋
The catalogue currently shows: 15 mg · 30 tablets; 15 mg · 90 tablets; 15 mg modified-release tablets · 98 tablets; 30 mg · 30 tablets. Check the complete strength, dosage form and pack description against the prescription and medicine box.
03Who manufactures Rinvoq?＋
Catalogue records currently name: AbbVie Deutschland GmbH & Co. KG, Orifarm GmbH, Abacus Medicine A/S. This field may identify a manufacturer, marketing-authorisation holder, marketing company or supplier; confirm the exact role on the pack leaflet and official regulatory record.
04Do the listed options confirm stock or access?＋
No. A catalogue record does not confirm current stock, authorisation in a particular country, clinical suitability, import permission or access.
05What affects a possible estimated medicine cost for Rinvoq?＋
A possible cost depends on the exact strength, dosage form, pack, quantity, destination and regulatory jurisdiction. Any amount provided after an enquiry is an indicative medicine-cost estimate only, not a selling price for Rinvoq, payment request, stock guarantee or binding offer.
06Can I buy Rinvoq from this website?＋
No. This website does not sell, take payment for, prescribe, import, dispense or deliver medicines. The form creates an independent consultancy enquiry only.